Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC

NCT05386524 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: sintilimab
DRUG: bevacizumab biosimilar
DRUG: pegylated liposomal doxorubicin

Sponsor

Fudan University